Literature DB >> 16482643

Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis.

Carol A Wallace1, Angelo Ravelli, Bin Huang, Edward H Giannini.   

Abstract

OBJECTIVE: To begin the validation process of the preliminary criteria for inactive disease (ID), clinical remission on medication (CRM), and clinical remission off medication (CR) in children with select forms of juvenile idiopathic arthritis (JIA).
METHODS: We used the OMERACT filter paradigm to estimate the validity of the criteria within each of the filter's 3 components: truth, discrimination, and feasibility, in 5 categories of JIA: systemic arthritis, persistent and extended oligoarthritis, and rheumatoid factor-positive and negative polyarthritis. Data sources for determining validity estimates included a Delphi questionnaire survey sent to 246 pediatric rheumatologists in 34 countries, a consensus conference attended by 20 senior pediatric rheumatologists representing 9 countries, a retrospective chart review of 437 patients with JIA from 3 tertiary care clinics who had been followed between 4 and 22 years, and the literature.
RESULTS: Truth component: face and content validity. These aspects of validity were largely established via the Delphi questionnaire exercise and the consensus conference. Using an 80% consensus level, participants felt that a set of non-redundant variables could effectively differentiate the clinical states of ID, CRM, and CR. Criterion validity could not be irrefutably established because no gold standard for inactive disease exists for JIA. As an alternative, published investigations of remission in JIA were used to estimate concurrent and convergent validity, as surrogates for criterion validity and as indicators of overall construct validity. Correlational analyses revealed the new criteria to have good construct validity. Discrimination component: the criteria demonstrated moderate to high levels of classification, prognosis, and responsiveness (sensitivity to change) using data from the chart review. Patients who were able to attain CR remained disease-free for substantially longer periods than did those who attained only ID or CRM. Responsiveness was evidenced by the ability of the criteria to allow movement of most patients between the disease states, consistent with what is known of the course of the disease. Feasibility component: Results of the Delphi and consensus conference produced a set of criteria that are easily, quickly, and inexpensively completed in the physician's office, and present minimal or no risk to the patient.
CONCLUSION: The preliminary criteria demonstrated moderate to excellent validity characteristics in some, but not all components of the OMERACT filter. Prospective validation studies are under way.

Entities:  

Mesh:

Year:  2006        PMID: 16482643

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  24 in total

Review 1.  Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.

Authors:  Thomas Broughton; Kate Armon
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

Review 2.  Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Authors:  Heinrike Schmeling; Gerd Horneff; Susanne M Benseler; Marvin J Fritzler
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

3.  Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.

Authors:  Takayuki Kishi; William Warren-Hicks; Nastaran Bayat; Ira N Targoff; Adam M Huber; Michael M Ward; Lisa G Rider
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

4.  Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016.

Authors:  Esi M Morgan; Meredith P Riebschleger; Jennifer Horonjeff; Alessandro Consolaro; Jane E Munro; Susan Thornhill; Timothy Beukelman; Hermine I Brunner; Emily L Creek; Julia G Harris; Daniel B Horton; Daniel J Lovell; Melissa L Mannion; Judyann C Olson; Homaira Rahimi; Maria Chiara Gallo; Serena Calandra; Angelo Ravelli; Sarah Ringold; Susan Shenoi; Jennifer Stinson; Karine Toupin-April; Vibeke Strand; Clifton O Bingham
Journal:  J Rheumatol       Date:  2017-08-15       Impact factor: 4.666

Review 5.  Remission in juvenile idiopathic arthritis: current facts.

Authors:  Susan Shenoi; Carol A Wallace
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

6.  Correlation of mean platelet volume, neutrophil-to-lymphocyte ratio, and disease activity in children with juvenile ıdiopathic arthritis.

Authors:  Ali Güneş; Aydın Ece; Velat Şen; Ünal Uluca; Fesih Aktar; İlhan Tan; Servet Yel; İlyas Yolbaş
Journal:  Int J Clin Exp Med       Date:  2015-07-15

7.  Development and retrospective validation of the juvenile spondyloarthritis disease activity index.

Authors:  Pamela F Weiss; Robert A Colbert; Rui Xiao; Chris Feudtner; Timothy Beukelman; Esi Morgan DeWitt; Ilaria Pagnini; Tracey B Wright; Carol A Wallace
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-12       Impact factor: 4.794

Review 8.  Methods of formal consensus in classification/diagnostic criteria and guideline development.

Authors:  Raj Nair; Rohit Aggarwal; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2011-03-21       Impact factor: 5.532

9.  Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging?

Authors:  Amanda Brown; Raphael Hirsch; Tal Laor; Michael J Hannon; Marc C Levesque; Terence Starz; Kimberly Francis; C Kent Kwoh
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

10.  American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Hermine I Brunner; Michael J Holland; Michael W Beresford; Stacy P Ardoin; Simone Appenzeller; Clovis A Silva; Francisco Flores; Beatrice Goilav; Pinar Ozge Avar Aydin; Scott E Wenderfer; Deborah M Levy; Angelo Ravelli; Raju Khubchandani; Tadej Avcin; Marisa S Klein-Gitelman; Nicolino Ruperto; Brian M Feldman; Jun Ying
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-05       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.